Market Overview

Biotech Bubble Valuations From Sam Islay

Share:
Related HNT
UBS Downgrades Molina Healthcare Following Q1 Miss
Benzinga's Volume Movers
Related IBB
A Tough Day For Some Biotech Bulls
The Things You Need To Know Ahead Of Mylan's Q3 Earnings
Here's Why The Nasdaq Is Down (Seeking Alpha)

Editor's note: A previous version of this story said ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) was among Isaly's picks. Isaly said the company "has done great this year," but he is looking at other stocks.

OrbiMed Advisors managing partner Sam Isaly told CNBC that biotech could be volatile, however, the valuations were "sensible."

Isaly's top picks included:

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Actelion Ltd (OTC: ALIOF)

Molina Healthcare, Inc. (NYSE: MOH)

Health Net, Inc. (NYSE: HNT)

Isaly said that the performance of the industry had been "great" over the past three to five years and that explosive growth in new products was expected to drive biotech stocks higher.

The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) had gained nearly 50 percent over the past 12 months and closed at $340.08 Wednesday, down 0.98 percent.

Latest Ratings for HNT

DateFirmActionFromTo
Nov 2015SusquehannaMaintainsNeutral
Aug 2015BMO CapitalMaintainsMarket Perform
Aug 2015BarclaysMaintainsUnderweight

View More Analyst Ratings for HNT
View the Latest Analyst Ratings

Posted-In: Orbimed Advisors Sam IsalyAnalyst Color Biotech CNBC Analyst Ratings Media General

 

Related Articles (HNT + ALIOF)

View Comments and Join the Discussion!